Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Pronzato

Showing results (1-10 of 95) with videos related to

Pageof 10
Sort By:
Future Oncology (London, England)|April 27, 2017
Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancerPaolo Pronzato
Drugs|January 17, 2008
New therapeutic options for chemotherapy-resistant metastatic breast cancer: the epothilonesPaolo Pronzato
Cancer Treatment Reviews|May 27, 2006
Cancer-related anaemia management in the 21st centuryPaolo Pronzato
Clinical Breast Cancer|January 23, 2009
New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerationsAlessandra Gennari, Paolo Pronzato
Future Oncology (London, England)|September 19, 2014
Treatment options in HR⁺/HER2⁻ advanced breast cancer patients pretreated with nonsteroidal aromatase inhibitors: what does current evidence tell us?Sabino De Placido, Paolo Pronzato
Tumori|April 21, 2016
The OECI certification/designation program: the Genoa experienceGiovanni Orengo, Paolo Pronzato, Manlio Ferrarini
Breast Care (Basel, Switzerland)|October 30, 2023
Biomarkers: Which Ones Do We Really Need Today?Angelo Paradiso, Sara Bravaccini, Paolo Pronzato
Critical Reviews in Oncology/Hematology|September 20, 2005
Epoetin beta therapy in patients with solid tumoursPaolo Pronzato, Jacek Jassem, Jose Mayordomo
Future Oncology (London, England)|July 11, 2013
Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patientsClaudia Bighin, Paolo Pronzato, Lucia Del Mastro
Le Infezioni in Medicina|March 16, 2020
Biosimilar pegfilgrastim and adherence to guidelines for chemotherapy-induced neutropenia and infections in cancer patientsMarco Danova, Andrea Antonuzzo, Federico Spandonaro, et al.
Pageof 10

Showing results (1-10 of 95) with videos related to

Sort By:
Pageof 10
Future Oncology (London, England)|April 27, 2017
Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancerPaolo Pronzato
Drugs|January 17, 2008
New therapeutic options for chemotherapy-resistant metastatic breast cancer: the epothilonesPaolo Pronzato
Cancer Treatment Reviews|May 27, 2006
Cancer-related anaemia management in the 21st centuryPaolo Pronzato
Clinical Breast Cancer|January 23, 2009
New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerationsAlessandra Gennari, Paolo Pronzato
Future Oncology (London, England)|September 19, 2014
Treatment options in HR⁺/HER2⁻ advanced breast cancer patients pretreated with nonsteroidal aromatase inhibitors: what does current evidence tell us?Sabino De Placido, Paolo Pronzato
Tumori|April 21, 2016
The OECI certification/designation program: the Genoa experienceGiovanni Orengo, Paolo Pronzato, Manlio Ferrarini
Breast Care (Basel, Switzerland)|October 30, 2023
Biomarkers: Which Ones Do We Really Need Today?Angelo Paradiso, Sara Bravaccini, Paolo Pronzato
Critical Reviews in Oncology/Hematology|September 20, 2005
Epoetin beta therapy in patients with solid tumoursPaolo Pronzato, Jacek Jassem, Jose Mayordomo
Future Oncology (London, England)|July 11, 2013
Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patientsClaudia Bighin, Paolo Pronzato, Lucia Del Mastro
Le Infezioni in Medicina|March 16, 2020
Biosimilar pegfilgrastim and adherence to guidelines for chemotherapy-induced neutropenia and infections in cancer patientsMarco Danova, Andrea Antonuzzo, Federico Spandonaro, et al.
Pageof 10